SCHEMBL2932218

SCHEMBL2932218

N#Cc1cc(-c2ccncc2)c(-c2ccc(F)cc2)nc1Cl

nearest known ligand 0.49

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
CNR1 P21554 6/20 0.49
CNR2 P34972 3/20 0.49
SQOR Q9Y6N5 1/20 0.47
MAPK14 Q16539 8/20 0.45
MAPK13 O15264 4/20 0.45
MAPK12 P53778 4/20 0.45
MAPK11 Q15759 4/20 0.45
CSNK1D P48730 1/20 0.45
CSNK1E P49674 1/20 0.45
CYP1A2 P05177 1/20 0.45
CYP2C9 P11712 1/20 0.45
CYP2C19 P33261 1/20 0.45
NPSR1 Q6W5P4 1/20 0.45
GCGR P47871 3/20 0.44
ALOX5 P09917 1/20 0.44
SRC P12931 1/20 0.43
BRAF P15056 1/20 0.43
KDR P35968 1/20 0.43
MAPK10 P53779 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2932221 0.86 RPS6KA3 (0.40) CNR1CNR2MAPK14MAPK13MAPK12
SCHEMBL2930455 0.85 SQOR (0.48) CNR1CNR2SQORMAPK14MAPK13
SCHEMBL3841687 0.84 SQOR (0.47) CNR1CNR2SQORMAPK14MAPK13
SCHEMBL8093828 0.83 CNR1 (0.52) CNR1CNR2MAPK14MAPK13MAPK12
SCHEMBL8087025 0.81 PTGS2 (0.54)
SCHEMBL19835709 0.81 CNR1 (0.55) CNR1CNR2CYP1A2CYP2C9CYP2C19
SCHEMBL8776847 0.80 CNR1 (0.52) CNR1CNR2CYP1A2CYP2C9CYP2C19
SCHEMBL8776749 0.79 PTGS2 (0.47) CNR1CNR2CYP1A2CYP2C9CYP2C19
SCHEMBL13498508 0.78 NPSR1 (0.69) CNR1CNR2CYP1A2CYP2C9CYP2C19
SCHEMBL3626102 0.76 CNR1 (0.65) CNR1CNR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8536194-B2 Pyrazolopyridine derivates PALAU PHARMA, S.A. (ES) 2013-09-17 US disclosed
EP-1611131-B1 PYRAZOLOPYRIDINE DERIVATES PALAU PHARMA SA (ES) 2010-09-15 EP disclosed
US-20090286983-A1 Pyrazolopyridine Derivates PALAU PHARMA, S.A. (ES) 2009-11-19 US disclosed
US-20090005377-A1 Pyrazolopyridine Derivates PALAU PHARMA, S.A. (ES) 2009-01-01 US disclosed
US-7468376-B2 Pyrazolopyridine derivates PALAU PHARMA, S.A. (ES) 2008-12-23 US disclosed
US-20060167040-A1 Pyrazolopyridine derivates J. URIACH Y COMPANIA S.A. (ES) 2006-07-27 US disclosed
EP-1611131-A1 PYRAZOLOPYRIDINE DERIVATES J. Uriach y Compagnia S.A. (ES) 2006-01-04 EP disclosed
WO-2004076450-A1 PYRAZOLOPYRIDINE DERIVATES J. Uriach Y Compañia S.A. (ES) 2004-09-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060167040-A1 Pyrazolopyridine derivates MAPK1, MAP4K2, MAP4K3 CNR1 2230/4885CNR2 2514/4885SQOR 823/4885
US-20090286983-A1 Pyrazolopyridine Derivates MAPK1, MAPK4, MAP4K2 CNR1 3068/4885CNR2 3458/4885SQOR 753/4885
US-20090005377-A1 Pyrazolopyridine Derivates MAPK1, MAPK4, MAP4K2 CNR1 3068/4885CNR2 3458/4885SQOR 753/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.